Rocket Pharmaceuticals Inc
RCKT
NASDAQ
Biotechnology
$3.47
USD
+0.13 (+3.89%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $368.29M
Volume 1.2M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-17.25M
TTM
+93.3%
YoY
Operating Cash Flow
$-170.27M
TTM
+16.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 25.0 | 18.4 | 14.7 | 17.1 | 17.4 |
Other Operating Expenses | 3.5 | -0.2 | -0.1 | 0.0 | 0.0 |
Total Operating Expenses | 71.1 | 52.2 | 44.0 | 48.5 | 46.9 |
Operating Income | -71.1 | -52.2 | -44.0 | -48.5 | -46.9 |
EBITDA | -65.6 | -49.7 | -42.4 | -46.9 | -45.4 |
Other Income / Expense | 2.2 | 1.7 | 1.2 | 0.0 | 178.9 |
Total Other Income / Expense | 2.2 | 1.9 | 1.4 | -0.3 | 178.8 |
Income Before Income Taxes | -68.9 | -50.3 | -42.5 | -48.8 | 131.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 8.6 |
Net Income | -68.9 | -50.3 | -42.5 | -47.6 | 123.2 |
Consolidated Net Income / Loss | -68.9 | -50.3 | -42.5 | -48.8 | 123.2 |
Net Income Attributable to Common Shareholders | -68.9 | -50.3 | -42.5 | -47.6 | 123.2 |
Basic EPS | -$0.62 | -$0.45 | -$0.38 | -$0.42 | $1.09 |
Diluted EPS | -$0.62 | -$0.45 | -$0.38 | -$0.42 | $1.08 |
Basic Shares Outstanding | 111.0M | 111.6M | 111.8M | 112.1M | 112.8M |
Diluted Shares Outstanding | 111.0M | 111.6M | 111.8M | 112.1M | 114.5M |